celecoxib has been researched along with Neoplastic Processes in 1 studies
Neoplastic Processes: The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we assessed a combination of chidamide plus celecoxib (called CC-01) combined with programmed cell death protein 1 (PD-1) blockade in a CT26 model as potent tumor microenvironment (TME) regulator." | 1.72 | CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. ( Chao, YS; Chen, CN; Chen, JS; Chou, CH; Chu, SH; Wu, YH; Yang, MH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JS | 1 |
| Chou, CH | 1 |
| Wu, YH | 1 |
| Yang, MH | 1 |
| Chu, SH | 1 |
| Chao, YS | 1 |
| Chen, CN | 1 |
1 other study available for celecoxib and Neoplastic Processes
| Article | Year |
|---|---|
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Topics: Adenocarcinoma; Aminopyridines; Animals; Antibodies, Monoclonal; Benzamides; Celecoxib; Cell Line, T | 2022 |